•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Patterson-UTI Energy, Inc. (PTEN) Q2 2026 Earnings Call Transcript
Here Are Friday’s Top Wall Street Analyst Research Calls: Blackstone Mortgage, Boston Scientific, Edison International, Ford, GoDaddy, International Paper, Roblox, Saia, and More
Patterson-UTI Energy Q2 Earnings Call Highlights
Patterson-UTI (PTEN) Reports Break-Even Earnings for Q2
Patterson-UTI (PTEN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Patterson-UTI Energy Reports Financial Results for the Quarter Ended June 30, 2026
Patterson-UTI Energy to Report Q2 Earnings: What's in Store?
Wall Street Analysts Predict a 25.83% Upside in Patterson-UTI (PTEN): Here's What You Should Know
Are Investors Undervaluing PattersonUTI Energy (PTEN) Right Now?
2 Top-Ranked Energy Stocks to Ride Oil's Rally Above $80
Patterson-UTI (PTEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Fresh U.S.-Iran Conflicts Could Extend Energy Rally: 2 Bargains Remain
Caris Life Sciences Expands Precision Oncology in Metastatic Prostate Cancer with PTEN IHC Testing
Patterson-UTI Energy Announces Second Quarter Earnings Conference Call and Webcast
Is PattersonUTI Energy (PTEN) Stock Outpacing Its Oils-Energy Peers This Year?
Patterson-UTI Reports Drilling Activity for June 2026
Is PattersonUTI Energy (PTEN) Stock Undervalued Right Now?
After Plunging 24.8% in 4 Weeks, Here's Why the Trend Might Reverse for Patterson-UTI (PTEN)
Patterson-UTI Energy Inc: Consider Holding On To This Oil Drilling Company As The Strait Of Hormuz Reopens
TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer